AzaSite^®(azithromycin ophthalmic solution) 1%

AzaSite is a macrolide antibiotic indicated in the U.S. for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC cornyeform group G,* Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae. AzaSite was launched in the U.S. in August 2007 by Inspire Pharmaceuticals, Inc., now a subsidiary of Merck & Co., Inc. (NYSE:MRK).,InSite’s commercial licensing partner for AzaSite in the U.S. and Canada.

* Efficacy for this organism was studied in fewer than 10 infections.

AzaSite contains the drug azithromycin and is formulated with our patented DuraSite^® drug-delivery technology. Azithromycin is a broad-spectrum antibiotic that is used to treat a variety of bacterial infections. AzaSite represents the first ophthalmic application of azithromycin.

AzaSite^® is a registered trademark owned by InSite Vision, Inc. and is licensed by Inspire Pharmaceuticals, a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK)
For information regarding the sale or use of AzaSite^® in the United States and Canada Click here or call (888) 881-4696.
For full prescribing information for AzaSite^® Click here.

Besivance^® (besifloxacin ophthalmic suspension) 0.6%

Besivance is a DuraSite formulation of besifloxacin, a broad spectrum ocular antibiotic approved by the FDA in May 2009 to treat bacterial conjunctivitis (pink eye). An advantage of Besivance is a faster rate of resolution of the infection that may reduce the duration of the illness and reduce the chances of infecting others. Besivance was developed by Bausch & Lomb and launched in the United States in the second half of 2009.